To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com


Molecular Profile CD274 positive
Therapy Atezolizumab + Nab-paclitaxel
Indication/Tumor Type triple-receptor negative breast cancer
Response Type sensitive

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive triple-receptor negative breast cancer sensitive Atezolizumab + Nab-paclitaxel Phase III Actionable In a Phase III trial (IMpassion130), Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) resulted in improved progression-free survival (7.5 vs 5.0 months, HR=0.62, p<0.001) and overall survival (25.0 vs 15.5 months, HR=0.62) compared to placebo in patients with CD274 (PD-L1)-positive (>1%), advanced triple-receptor negative breast cancer (PMID: 30345906; NCT02425891). detail... 30345906 detail...
CD274 positive triple-receptor negative breast cancer sensitive Atezolizumab + Nab-paclitaxel Guideline Actionable The combination of Tecentriq (atezolizumab) and Abraxane (nab-paclitaxel) is included in guidelines as first line therapy for CD274 (PD-L1)-positive patients with triple-negative breast cancer (PMID: 34678411; ESMO.org). 34678411 detail...
PubMed Id Reference Title Details
(30345906) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. Full reference...
ESMO Clinical Practice Guidelines Full reference...
Full reference...
Tecentriq (atezolizumab) FDA Drug Label Full reference...
(34678411) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Full reference...